Literature DB >> 17568926

[Acute bronchiolitis, an updated review].

Werther Brunow de Carvalho1, Cíntia Johnston, Marcelo Cunio Fonseca.   

Abstract

Acute bronchiolitis (AB) is a frequent cause of hospitalization among children and its main etiological agent is respiratory syncytial virus (RSV). It occurs epidemically during autumn and winter. Some populations of children such as premature newborns, infants with congenital heart disease and those with chronic lung disease, immunocompromised, undernourished, among others, present increased morbidity and mortality risk. The virus multiplies in epithelial ciliated cells while inflammation and cellular debris cause obstruction of the airways, hyperinflation, atelectasis, and wheezing and gas exchange imbalance. Definitive evidence still does not exist about treatment of this disease, Treatment includes oxygen therapy, hydration, inhaled beta-2 agonists, racemic epinephrine, recombinant DNase and respirotherapy, among others. Prophylactic measures include administration of monoclonal antibodies. The majority of children with AB, independent of disease severity, recover without sequels. The natural course of this disease usually varies, from seven to ten days ,however some children may not recover for weeks.

Entities:  

Mesh:

Year:  2007        PMID: 17568926     DOI: 10.1590/s0104-42302007000200027

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.209


  2 in total

1.  Comparative analysis of the effects of two chest physical therapy interventions in patients with bronchiolitis during hospitalization period.

Authors:  Renata Remondini; Adriana Zamprônio dos Santos; Giselle de Castro; Cristiane do Prado; Luiz Vicente Ribeiro Ferreira da Silva Filho
Journal:  Einstein (Sao Paulo)       Date:  2014 Oct-Dec

Review 2.  Update on viral community-acquired pneumonia.

Authors:  Ozéas Galeno da Rocha Neto; Ricardo Ferreira Leite; Bruno Guedes Baldi
Journal:  Rev Assoc Med Bras (1992)       Date:  2013 Jan-Feb       Impact factor: 1.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.